Taspoglutide
Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.
Online Inquiry
| CAT# | 10-101-176 |
| CAS | 275371-94-3 |
| Synonyms/Alias | UNII-2PHK27IP3B |
| M.F/Formula | C152H232N40O45 |
| M.W/Mr. | 3339.70948 |
| Sequence | H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Aib-Arg-NH2 |
| Labeling Target | Glucagon-like peptide 1 (GLP-1) receptor |
| Application | Taspoglutide is developed for treatment of type 2 diabetes |
| Activity | Agonist |
| Areas of Interest | Metabolic Disease |
| Source# | Synthetic |
Storage | -20°C |
BoilingPoint | N/A |
Melting Point | N/A |
Write a review
Ask a question
My Review for Taspoglutide
Required fields are marked with *
×
Ask a Question for Taspoglutide
Required fields are marked with *
×
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
